Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Prostate
Descriptor: Reviews

Reference Number: 785
Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 91, 31-67 (2004)
PubMed link      E-mail link

Reference Number: 1173
Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem. 4, 107-19 (2012)
PubMed link      E-mail link

Reference Number: 1209
Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20, 1677-84 (2011)
PubMed link      E-mail link

Reference Number: 1325
Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 19, 90-8 (2013)
PubMed link      E-mail link

Reference Number: 1640
Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 33, 581-94 (2014)
PubMed link      E-mail link

Reference Number: 1652
Ojemuyiwa MA, Madan RA, Dahut WL. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs. 19, 459-70 (2014)
PubMed link      E-mail link